- Investing Ideas
- /
- Argentinian Pharmaceuticals & Biotech Consumer Staple Stocks
Argentinian Pharmaceuticals & Biotech Consumer Staple Stocks
UPDATED May 27, 2024
Companies in consumer staple industries including durables, food, beverage, tobacco, and household and personal products.
30 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$17,820.00 | 3.5% | 373.2% | US$727.0b | US$18,767.05 | PE118.5x | E27.3% | 0.6% | ||
LLYD | US$18.00 | 17.3% | 127.0% | US$727.0b | US$18.96 | PE118.5x | E27.3% | 0.6% | ||
DJNJ2 | US$815.00 | 0% | n/a | US$391.1b | US$876.26 | PE28x | E9.4% | 2.9% | ||
JNJ | US$12,241.50 | 1.4% | 143.6% | US$353.7b | US$14,369.03 | PE20.7x | E6.9% | 3.4% | ||
DJNJ3 | US$1,250.00 | 0% | n/a | US$353.7b | US$1,467.25 | PE20.7x | E6.9% | 3.4% | ||
JNJD | US$10.00 | -3.4% | -6.5% | US$353.7b | US$11.74 | PE20.7x | E6.9% | 3.4% | ||
MRK | US$31,796.50 | 1.7% | 198.2% | US$328.0b | US$34,838.20 | PE142.2x | E24.1% | 2.4% | ||
MRKD | US$28.45 | 0.2% | 18.5% | US$328.0b | US$32.01 | PE138.5x | E24.1% | 2.4% | ||
ABBVD | US$15.50 | -7.7% | 3.3% | US$277.3b | US$18.19 | PE46.1x | E23.3% | 4.0% | ||
ABBV | US$19,133.00 | -1.9% | 187.1% | US$277.3b | US$22,448.74 | PE46.1x | E23.3% | 4.0% | ||
AZN | UK£47,328.00 | -0.05% | 172.3% | UK£186.5b | UK£51,272.92 | PE38.5x | E14.6% | 2.0% | ||
AZND | UK£40.25 | 3.2% | 5.0% | UK£186.5b | UK£43.60 | PE38.5x | E14.6% | 2.0% | ||
TMO | US$32,057.50 | 1.9% | 181.0% | US$222.9b | US$35,131.37 | PE36.2x | E10.6% | 0.3% | ||
NVS | CHF30,856.50 | -0.04% | 161.9% | CHF185.9b | CHF33,036.85 | PE22.6x | E10.0% | 3.6% | ||
NVSD | CHF23.70 | -2.3% | n/a | CHF185.9b | CHF25.37 | PE22.6x | E10.0% | 3.6% | ||
TMOD | US$27.00 | 0% | n/a | US$200.3b | US$32.62 | PE33.2x | E15.5% | 0.3% | ||
AMGND | US$10.30 | -9.3% | n/a | US$164.1b | US$10.85 | PE42.8x | E18.0% | 3.0% | ||
AMGN | US$12,363.00 | -1.4% | 247.3% | US$164.1b | US$13,025.41 | PE42.8x | E18.0% | 3.0% | ||
PFE | US$8,734.50 | 2.2% | 93.5% | US$163.7b | US$9,850.37 | PS2.9x | E30.6% | 5.9% | ||
PFED | US$7.35 | 0.5% | -26.5% | US$163.7b | US$8.29 | PS2.9x | E30.6% | 5.9% | ||
GSKD | UK£12.00 | 0% | n/a | UK£72.4b | UK£13.74 | PE16.1x | E12.2% | 3.3% | ||
GSK | UK£13,600.00 | 2.2% | 228.7% | UK£71.0b | UK£15,575.74 | PE16.1x | E12.2% | 3.3% | ||
BMY | US$16,714.50 | -0.9% | 61.2% | US$83.6b | US$21,959.01 | PS1.8x | E44.7% | 5.9% | ||
GILD | US$19,719.00 | -2.2% | 112.5% | US$81.8b | US$25,527.57 | PE164.2x | E36.5% | 4.8% |